S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.41 (-1.57%)
MSFT   398.56 (-1.41%)
META   481.27 (-4.09%)
GOOGL   153.05 (-1.90%)
AMZN   174.63 (-2.56%)
TSLA   148.33 (-1.07%)
NVDA   805.15 (-4.91%)
AMD   148.11 (-4.49%)
NIO   3.81 (-4.75%)
BABA   68.48 (-0.58%)
T   16.30 (-0.18%)
F   12.08 (+0.17%)
MU   107.11 (-4.31%)
GE   147.70 (-3.43%)
CGC   7.88 (+0.64%)
DIS   111.50 (-0.83%)
AMC   3.20 (+9.59%)
PFE   25.81 (+1.65%)
PYPL   61.85 (-0.40%)
XOM   119.85 (+1.12%)
Free Trial
NYSE:TMBR

Timber Pharmaceuticals (TMBR) Stock Price, News & Analysis

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)
Free TMBR Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.34
▼
$2.94
52-Week Range
N/A
Volume
26,307 shs
Average Volume
511,937 shs
Market Capitalization
$1.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipSocial Media
TMBR stock logo

About Timber Pharmaceuticals Stock (NYSE:TMBR)

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

TMBR Stock News Headlines

March 10, 2024 | businesswire.com
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
January 28, 2024 | msn.com
Timber Pharmaceuticals Announces Official Name Change
April 19, 2024 | Tips4Traders (Ad)
Uncover this 2024 Hidden Gem
Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.
January 13, 2024 | uk.investing.com
Timber Pharmaceuticals Inc (TMBRQ)
November 29, 2023 | finance.yahoo.com
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
November 29, 2023 | finance.yahoo.com
NYSE American to Suspend Trading Immediately in Timber Pharmaceuticals, Inc. (TMBR)
November 28, 2023 | tmcnet.com
Timber Pharmaceuticals Receives Court Approval of All "First Day" Motions to Support Business Operations & Discloses Communication From NYSE American
November 28, 2023 | finance.yahoo.com
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
April 19, 2024 | Tips4Traders (Ad)
Uncover this 2024 Hidden Gem
Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.
November 21, 2023 | seekingalpha.com
MVST, FBIO and VTVT among mid-day movers
November 17, 2023 | msn.com
Timber Pharmaceuticals files for Chapter 11 in wake of failed merger
November 16, 2023 | msn.com
Timber Pharma slips ahead of shareholder vote on merger
September 18, 2023 | finance.yahoo.com
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
August 29, 2023 | 247wallst.com
HC Wainwright Downgrades Timber Pharmaceuticals
August 28, 2023 | msn.com
HC Wainwright & Co. Downgrades Timber Pharmaceuticals (TMBR)
August 21, 2023 | benzinga.com
TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders
August 21, 2023 | markets.businessinsider.com
Dow Tumbles Over 100 Points; Timber Pharmaceuticals Shares Spike Higher
August 21, 2023 | msn.com
Timber to be taken private by LEO Pharma, stock soars 100%
August 21, 2023 | investorplace.com
Why Is Timber Pharmaceuticals (TMBR) Stock Up 96% Today?
August 21, 2023 | markets.businessinsider.com
US Stocks Mostly Higher; Nasdaq Jumps 100 Points
August 21, 2023 | marketwatch.com
Timber Pharmaceuticals Shares Soar on Takeover by LEO Pharma
August 21, 2023 | benzinga.com
Why Timber Pharmaceuticals Stock Is Skyrocketing Today
August 21, 2023 | finance.yahoo.com
LEO Pharma Signs Agreement to Acquire Timber Pharmaceuticals
August 21, 2023 | finance.yahoo.com
Timber Pharmaceuticals to be Acquired by LEO Pharma
August 15, 2023 | morningstar.com
Timber Pharmaceuticals Inc Ordinary Shares
July 3, 2023 | finance.yahoo.com
Timber Pharmaceuticals Discloses Communication From NYSE American
June 5, 2023 | msn.com
Timber Pharmaceuticals Soars as FDA Removes Hurdle
See More Headlines
Receive TMBR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Timber Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:TMBR
CUSIP
N/A
CIK
1504167
Web
www.timberpharma.com
Phone
(973) 314-9577
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-19,380,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-511.45%
Return on Assets
-180.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.50
Quick Ratio
0.50

Sales & Book Value

Annual Sales
$80,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.79 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,430,000
Free Float
3,378,000
Market Cap
$1.21 million
Optionable
Not Optionable
Beta
0.03
These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

TMBR Stock Analysis - Frequently Asked Questions

Should I buy or sell Timber Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Timber Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TMBR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMBR, but not buy additional shares or sell existing shares.
View TMBR analyst ratings or view top-rated stocks.

When did Timber Pharmaceuticals' stock split?

Timber Pharmaceuticals shares reverse split on the morning of Wednesday, November 9th 2022. The 1-50 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

This page (NYSE:TMBR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith